KRAS and non-small cell lung carcinoma: There is an urgent need for the development of rationally designed combinatorial treatment strategies that can overcome the development of drug resistance, while simultaneously expanding therapeutic indications, to BRAF non-V600-, KRAS-, or RTK-mutant NSCLC.